key: cord-0744818-i509zr97
authors: Waheed, Waqar; Carey, Magalie E.; Tandan, Sarah R.; Tandan, Rup
title: Post COVID‐19 vaccine small fiber neuropathy
date: 2021-04-28
journal: Muscle Nerve
DOI: 10.1002/mus.27251
sha: 9f9655bd95ba3a5cc0723d62410da21e85bb143f
doc_id: 744818
cord_uid: i509zr97

nan

The following laboratory tests were normal or negative: complete blood count, comprehensive metabolic profile, thyroidstimulating hormone, methylmalonic acid, folic acid, thiamine, pyri- With regard to SARS-CoV-2, a recent study from the United Kingdom found no association between COVID-19 and GBS. 4 Furthermore, the lack of significant homology between any SARS-CoV-2 genetic or linear protein structure and human linear protein F I G U R E 1 Three mm punch biopsies of skin undertaken confirmed multifocal small fiber neuropathy, suggested by loss of protein gene product 9.5 immunolabeled nerve fibers in the dorsum of left foot, over the extensor digitorum brevis muscle (2.1 fibers/mm of skin; normal >3.0) and left upper thigh at the level of ischial tuberosity (3.8 fibers/mm of skin; normal >6.0), and low normal intra-epidermal nerve fiber density (IENFD) in the calf segment, 10 cm above the lateral malleolus (4.7 fibers/mm of skin; normal >4.3). Scale bar represents 20 μm. Interpretation of IENFD was done by Corinthian Reference Laboratory, Benbrook, TX

A proposed taxonomy of isolated small fiber neuropathy

Small fiber neuropathy following vaccination

Guillain-Barré syndrome following influenza vaccines affords opportunity to improve vaccine confidence

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome

Advisory Committee on Immunization Practices (ACIP) meeting

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK

US Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System